Fig. 2
From: Defective transcription elongation in a subset of cancers confers immunotherapy resistance
TEdeff impairs the expression of stimulus-responsive genes and pathways. a Differential enrichment of Class I and II genes for the gene features defined in the Roadmap Epigenomics datasets. b Genomic lengths (left) and exon density (ratio of full mRNA/genomic length) profiles (right) of Class I and II genes (P: t-test). c Genomic length distributions of constituent genes in the Class I- and Class II-enriched (P < 0.0001, hypergeometric test) pathways (colored blue and red, respectively). d Scatter plot of average t-statistic of change in mRNA (y-axis) and corresponding total protein (x-axis) in TEdeff vs. TEprof samples across cancers. e Gene lengths of proteins that are repressed (average t-statistic <−1) or overexpressed (t-statistic >1) in TEdeff cancers. e A heatmap of some of the most consistent protein-level changes in TEdeff vs. TEprof samples in the indicated cancer types (P: t-test). f A diagram of representative pathways from commonly repressed and overexpressed phospho- and total proteins in F (blue: repressed, red: overexpressed). Compare the pathways with the mRNA-level profile in c. Boxplots:: middle line: median, boxed areas extend from the first to third quartile; whiskers show 1.5x inter-quartile range from the first (bottom) or third (top) quartile
